Zobrazeno 1 - 10
of 105
pro vyhledávání: '"R Alterini"'
Publikováno v:
Bone Marrow Transplantation. 19:275-281
The analysis of published survival curves can be used as the basis for conducting cost-effectiveness analyses in which two treatments are compared in terms of cost per life year saved. In patients with relapsed chemosensitive non-Hodgkin's lymphoma,
Publikováno v:
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. 147(6)
Among primary cutaneous B-cell lymphomas (CBCL), two main clinico-pathologic entities are recognized, i.e. marginal zone lymphoma (MZL), otherwise defined as extranodal MZL, MALT (Mucosa-Associated Lymphoid Tissue) type, and follicle center lymphoma
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nicola Pimpinelli, C. Delfino, L. Rigacci, Alessandro Pileri, R. Alterini, Vieri Grandi, S. Gunnella
Publikováno v:
Drugs and Cell Therapies in Hematology. 2:301
Correspondence: Nicola Pimpinelli, MD, PhD Dept. Surgery and Translational Medicine Division Dermatology University of Florence Medical School Viale Michelangiolo, 41 50125 Florence, Italy E mail: nicola.pimpinelli@unifi.it SUMMARY Brentuximab vedoti
Publikováno v:
Haematologica. 83(12)
Autor:
A M, Vannucchi, A, Bosi, S, Glinz, P, Pacini, S, Linari, R, Saccardi, R, Alterini, L, Rigacci, S, Guidi, L, Lombardini, G, Longo, M P, Mariani, P, Rossi-Ferrini
Publikováno v:
British journal of haematology. 103(3)
There is considerable interest in an autologous transplantation (AT) programme for patients with high-risk breast cancer; however, the issue of the incidence of occult bone marrow (BM) micrometastasis at diagnosis, and the cancer contamination of per
Publikováno v:
Oncology Reports.
The main therapeutic options currently available to induce remission in newly diagnosed cases of multiple myeloma include: i) melphalan at conventional doses without concurrent administration of interferon; ii) melphalan at conventional dose combined
Publikováno v:
Haematologica. 80(1)
Stem cell factor (SCF) has already been shown to participate in the regulation of erythro- and granulopoiesis. The aim of this study was to define the possible role of SCF in the regulation of megakaryocytopoiesis.Stem cell factor activity has been a